A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants
Clinical trial NCT06356259 · TERMINATED
Trial details
- NCT number
- NCT06356259
- Sponsor
- ImmunoRx Pharma Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-07
- Primary completion
- 2025-01-23
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.